Biotech Values

[flatlander_60048]

I'm not sure what yahoo's figures are based on. Page 18 of the Annual report released a couple weeks ago states 46% increase in product sales revenue 2018 over 2017. That is less than half of the prior year (91%). I know it's pretty lumpy but there are a number of moving parts (primarily revenue recognized from lump sum payments from collaboration partners). I think they need to get to 350,000 - 375,000 annualized cartridge sales to break even.

I think there is pent up demand for the an IVD Breast cancer solution underscored by the TailorX study. Also, the Chinese and Japanese partnerships should start bearing fruit during the 2nd year. I suspect that sales will see a major inflection point in 2020.

What I find somewhat intriguing and maybe a little scary is the ways that the ecosystem might be utilized. Education on partner drugs through cloud connections is probably great and a partial reason CDx partnerships. The mining of physician or clinic diagnostic trends might be illegal. That type of problem is probably a long way off considering the installed base is relatively tiny.

Regards
FL